Aethlon Medical, Inc. is a clinical-stage medical therapeutics company developing the Hemopurifier® device to treat cancer and viral infections, with ongoing clinical research and no reported revenue.


# Company Summary: Aethlon Medical, Inc.

## Core Business
- **Type:** Medical therapeutic company focused on developing the Hemopurifier® (HP), a clinical-stage immunotherapeutic device.
- **Purpose:** The device is intended to treat cancer, life-threatening viral infections, organ transplantation, and other significant unmet medical needs.

## Technology and Mechanism
- **Hemopurifier®:** An extracorporeal, lectin-affinity plasmapheresis device designed to remove:
  - Harmful extracellular vesicles (EVs) implicated in immune suppression, tumor metastasis, and disease progression.
  - Enveloped viruses such as Ebola, HIV, hepatitis-C, SARS-CoV-2, and others.
- **Design:** Can be used with FDA-approved dialysis machines or as a standalone closed system.
- **Regulatory Status:** FDA-designated as a “Breakthrough Device” for two indications:
  - Treatment of advanced/metastatic cancer unresponsive to standard therapies.
  - Treatment of life-threatening viruses with no current approved therapies.

## Clinical and Research Activities
- **Cancer (Oncology):**
  - Focus on treating solid tumors with reductions in EVs and improving immune response.
  - Conducting a Phase 1 safety, feasibility, and dose-finding trial in Australia with 3 treated patients as of June 26, 2025.
  - Formed a subsidiary in Australia to expand oncology clinical research.
  - Seeking approval to conduct similar trials in India.
- **Viral Infections:**
  - Used in small human studies for HIV, hepatitis-C, Ebola, and COVID-19 (SARS-CoV-2). 
  - Terminated COVID-19 studies due to low ICU patient volume but maintained a regulatory pathway for future outbreaks.
  - Open Investigational Device Exemption (IDE) for viral indications.
- **Preclinical Exploration:**
  - Published studies indicating removal of EVs from organ perfusates and blood.
  - Ongoing research into removing platelet-derived EVs and extracellular vesicles related to Long COVID.
- **Additional Potential Uses:** Ex vivo removal of microvesicular particles from discarded kidneys and investigation into organ transplantation applications.

## Operational Details
- **Employees:** 9 full-time employees as of June 26, 2025.
- **Manufacturing:** FDA-approved manufacturing at San Diego facility; working with FDA to qualify additional component suppliers.
- **Market & Competition:** Competes with blood filters like ExThera Medical. Industry is highly competitive, with large pharmaceutical, biotech, academic, and government players developing similar or alternative technologies.

## Revenue and Financials
- **Revenue:** No revenue reported for the fiscal years ending March 31, 2025 and 2024.
- **Research & Development Costs:** 
  - ~$2.2 million for fiscal year 2025.
  - ~$2.5 million for fiscal year 2024.
- **Employees:** 9 full-time employees.
- **Customer Base:** Currently involved in clinical trials with a small number of enrolled participants (e.g., 3 patients in the Australian cancer trial as of June 2025). No commercial sales or broad customer base reported.

## Other Details
- **Market Capitalization:** As of September 30, 2024, approximately $6.65 million, based on a share price of $3.73 and trading on NASDAQ.
- **Shares Outstanding:** 2,585,316 shares as of June 24, 2025, after a reverse stock split.
- **Intellectual Property:** Owns or has license rights to over 32 issued patents worldwide, with several patents expiring between 2027-2031, and actively pursuing additional patent applications.
- **Business Focus:** Developing and validating the Hemopurifier for multiple indications with ongoing clinical trials, while managing regulatory, manufacturing, and market challenges.



Aethlon Medical, Inc. is a medical technology company focused on developing innovative therapeutic devices for the treatment of infectious diseases and cancer.

# Aethlon Medical, Inc. Overview

## Business Description
Aethlon Medical, Inc. is a medical technology company that designs and develops advanced therapeutic devices and offers solutions for addressing unmet medical needs associated with infectious diseases and cancer. The primary focus of the company is its proprietary Aethlon ADAPT (Apheresis Device for Acute Processing and Treatment) platform, which is designed to remove lethal pathogens and their toxins from the bloodstream. This platform is applicable to various viral infections, including those resistant to treatment and those not adequately addressed by existing therapies.

### Key Products and Services
1. **Aethlon ADAPT Platform**: An advanced apheresis device aimed at filtering and removing pathogens from the blood. 
2. **Product Candidates**:
   - **HIV**: Aethlon has developed strategies for addressing HIV through its ADAPT technology.
   - **COVID-19**: The platform aims at addressing COVID-19 related complications by clearing the virus and inflammatory markers from the bloodstream.
   - **Cancer**: The device has applications in oncological therapies, focusing on removing cancerous cells and improving overall treatment efficacy.

## Financial Overview
- **Number of Employees**: The company employs approximately 25 full-time staff members, including executives and specialists in various roles within medical technology development.
- **Customers**: Aethlon Medical primarily serves hospitals, clinical research organizations, and healthcare professionals involved in infectious disease treatment and cancer care. Customer base specifics are not publicly disclosed.
- **Revenue**: For the fiscal year ending March 31, 2024, the company reported revenue of approximately **$2.4 million**, primarily from grants and small-scale commercialization efforts.
- **Net Income**: The company experienced a **net loss of approximately $5.4 million** for the same fiscal year, attributable to ongoing research, product development, and operational costs.

## Market Presence and Strategy
Aethlon Medical positions itself within the biopharmaceutical and medical device markets, striving to innovate and enhance therapeutic options for patients with severe health conditions. The company is focused on expanding its clinical trials and market reach, with plans to grow its product offerings and possibly establish partnerships with larger healthcare and research entities for broader distribution.

Through patented technology and a commitment to addressing significant medical needs, Aethlon Medical aims to improve clinical outcomes for patients worldwide. The company actively engages in fundraising and partnership discussions to support its R&D initiatives and clinical trials, enhancing its market potential and aims for future profitability.

AETHLON MEDICAL INC

10-K / June 26, 2025

10-K / August 15, 2024

10-K / June 26, 2025

Company Summary: Aethlon Medical, Inc.

Core Business

Technology and Mechanism

Clinical and Research Activities

Operational Details

Revenue and Financials

Other Details